113 related articles for article (PubMed ID: 18577454)
1. When binding is enough: nonactivating antibody formats.
Labrijn AF; Aalberse RC; Schuurman J
Curr Opin Immunol; 2008 Aug; 20(4):479-85. PubMed ID: 18577454
[TBL] [Abstract][Full Text] [Related]
2. Isotype selection for antibody-based cancer therapy.
Vukovic N; van Elsas A; Verbeek JS; Zaiss DMW
Clin Exp Immunol; 2021 Mar; 203(3):351-365. PubMed ID: 33155272
[TBL] [Abstract][Full Text] [Related]
3. Stability of IgG isotypes in serum.
Correia IR
MAbs; 2010; 2(3):221-32. PubMed ID: 20404539
[TBL] [Abstract][Full Text] [Related]
4. Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics.
Ng CL; Lim TS; Choong YS
Mol Biotechnol; 2024 Apr; 66(4):568-581. PubMed ID: 37742298
[TBL] [Abstract][Full Text] [Related]
5. Aggregation, immune complexes and immunogenicity.
Jefferis R
MAbs; 2011; 3(6):503-4. PubMed ID: 22123066
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the immune system's arsenal: producing human monoclonal antibodies for therapeutics and investigating immune responses.
Sullivan M; Kaur K; Pauli N; Wilson PC
F1000 Biol Rep; 2011; 3():17. PubMed ID: 21876728
[TBL] [Abstract][Full Text] [Related]
7. Considerations for the development of therapeutic monoclonal antibodies.
Swann PG; Tolnay M; Muthukkumar S; Shapiro MA; Rellahan BL; Clouse KA
Curr Opin Immunol; 2008 Aug; 20(4):493-9. PubMed ID: 18586093
[TBL] [Abstract][Full Text] [Related]
8. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
[TBL] [Abstract][Full Text] [Related]
9. R409K mutation prevents acid-induced aggregation of human IgG4.
Namisaki H; Saito S; Hiraishi K; Haba T; Tanaka Y; Yoshida H; Iida S; Takahashi N
PLoS One; 2020; 15(3):e0229027. PubMed ID: 32182240
[TBL] [Abstract][Full Text] [Related]
10. VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis.
Low S; Wu H; Jerath K; Tibolla A; Fogal B; Conrad R; MacDougall M; Kerr S; Berger V; Dave R; Villalona J; Pantages L; Ahlberg J; Li H; Van Hoorick D; Ververken C; Broadwater J; Waterman A; Singh S; Kroe-Barrett R
MAbs; 2020; 12(1):1709322. PubMed ID: 31924119
[TBL] [Abstract][Full Text] [Related]
11. Antibody Structure and Function: The Basis for Engineering Therapeutics.
Chiu ML; Goulet DR; Teplyakov A; Gilliland GL
Antibodies (Basel); 2019 Dec; 8(4):. PubMed ID: 31816964
[TBL] [Abstract][Full Text] [Related]
12. Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality.
Tam SH; McCarthy SG; Armstrong AA; Somani S; Wu SJ; Liu X; Gervais A; Ernst R; Saro D; Decker R; Luo J; Gilliland GL; Chiu ML; Scallon BJ
Antibodies (Basel); 2017 Sep; 6(3):. PubMed ID: 31548527
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function.
Escobar-Cabrera E; Lario P; Baardsnes J; Schrag J; Durocher Y; Dixit S
Antibodies (Basel); 2017 May; 6(2):. PubMed ID: 31548523
[TBL] [Abstract][Full Text] [Related]
14. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.
Li W; Zhu Z; Chen W; Feng Y; Dimitrov DS
Front Immunol; 2017; 8():1554. PubMed ID: 29181010
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
[TBL] [Abstract][Full Text] [Related]
16. Current progress in innovative engineered antibodies.
Strohl WR
Protein Cell; 2018 Jan; 9(1):86-120. PubMed ID: 28822103
[TBL] [Abstract][Full Text] [Related]
17. Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection.
Wu J; Ma XL; Tian L; Zhang CY; Wang BL; Hu YY; Gao XH; Zhou Y; Shen MN; Peng YF; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Cancer; 2017; 8(8):1338-1346. PubMed ID: 28638447
[No Abstract] [Full Text] [Related]
18. IgG4 Characteristics and Functions in Cancer Immunity.
Crescioli S; Correa I; Karagiannis P; Davies AM; Sutton BJ; Nestle FO; Karagiannis SN
Curr Allergy Asthma Rep; 2016 Jan; 16(1):7. PubMed ID: 26742760
[TBL] [Abstract][Full Text] [Related]
19. Generation and preclinical characterization of an antibody specific for SEMA4D.
Fisher TL; Reilly CA; Winter LA; Pandina T; Jonason A; Scrivens M; Balch L; Bussler H; Torno S; Seils J; Mueller L; Huang H; Klimatcheva E; Howell A; Kirk R; Evans E; Paris M; Leonard JE; Smith ES; Zauderer M
MAbs; 2016; 8(1):150-62. PubMed ID: 26431358
[TBL] [Abstract][Full Text] [Related]
20. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
